Why ALD Newborn-Screening Programs Can Differ

By Lucas Project Foundation

Read the original systematic review

Families comparing screening experiences may hear different descriptions of tests and follow-up. A review published September 30, 2026 helps explain why.

Researchers examined 13 publications describing ALD newborn-screening programs from 2013 through June 2026. All used the blood marker C26:0-LPC, but laboratory methods, cutoffs, screening steps and follow-up approaches differed. Some programs also differed in whether screening was designed to identify boys alone or babies of both sexes.

The review highlights the opportunity to identify children before symptoms and connect them with monitoring. It also identifies work still needed: clearer interpretation of uncertain genetic findings, more consistent methods and longer-term follow-up.

What this means for your family

This is a review of published programs, not a current map of screening availability. Its results cannot tell you whether your own baby has ALD or what will happen next.

A useful question is: “How does our screening program confirm an out-of-range result, and who will explain the next steps?” You do not have to work that out by comparing other families’ reports.

Further reading: HRSA’s screening and follow-up information.

Previous
Previous

ALD Newborn Screening in Denmark: What a Three-Step Study Tested

Next
Next

Expanded Cord Blood Transplant for Cerebral ALD: What One Case Can Tell Us